Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort

(2012) Laura E Targownik et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

The Jak Inhibitor CP-690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells

(2010) V. D. K. D. Sewgobind et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia

(2010) Nihad A.M. Tamimi et al.   BJU INTERNATIONAL

A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder

(2010) Francois A. Giuliano et al.   BJU INTERNATIONAL

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

(2010) Mark E. Flanagan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Patient reported symptoms during an ulcerative colitis flare: A Qualitative Focus Group Study

(2009) Akbar K. Waljee et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY